VALIRX PLC
("ValiRx", the "Company" or the "Group")
Total Voting Rights and Block Listing Update
London, UK 1 March 2021: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.
In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue is 65,049,156. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.
The figure of 65,049,156 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Warrant Update
As at the date of this announcement, 8,951,399 warrants at 13p have been exercised bringing gross proceeds of circa £1,163,682 (of which circa £21,666 were received in February 2021) to the Company and 83,333 warrants exercisable at 13p are outstanding. The aggregate number of warrants exercised at 13p in the month of March 2021 (and subject to the block listing announced on 19 August 2020) will be notified in the monthly total voting rights update on 1 April 2021.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information please contact:
About ValiRx ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/ |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
